Alan S. Wayne, MD

Chair, Department of Pediatrics

Professor of Pediatrics, Medicine, and Cancer Biology, Keck School of Medicine of USC

Pediatrician-in-Chief and Senior Vice President of Academic Affairs

Pasadena Guild Chair Children's Hospital Los Angeles

Image of Alan S. Wayne, MD
Is this your profile? Click to edit

Overview

Alan S. Wayne, MD serves as Chair of the Department of Pediatrics at the Keck School of Medicine of USC and Senior Vice President of Academic Affairs and Pediatrician-in-Chief at Children’s Hospital Los Angeles (CHLA). Dr. Wayne is Professor of Pediatrics and Medicine at the Keck School of Medicine of USC. In these roles, Dr. Wayne oversees the Department’s clinical care delivery, medical education, and research programs, and leads the departmental strategy, faculty affairs, and budget management in the context of the missions of USC and CHLA.

Dr. Wayne’s primary research efforts are directed toward the development of new treatment approaches for leukemias and lymphomas, with a focus on targeted, immune-based, and cellular therapies. He is the Medical Director of the Therapeutic Advances in Childhood Leukemia/Lymphoma (TACL) Consortium, a multinational clinical trials group headquartered at CHLA. He has an ongoing leadership role in the development of genetically modified chimeric antigen receptor (CAR) T-cells for childhood hematologic malignancies. Additionally, he plays a leadership role in international efforts in the area of post-transplant relapse of hematologic malignancies, the primary aim of which is to study the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation.

Board-certified in pediatric hematology-oncology, Dr. Wayne attended the Honors Program in Medical Education obtaining his BS and MD degrees from Northwestern University. He conducted internship, residency, and chief residency in pediatrics at Boston Children’s Hospital followed by pediatric hematology-oncology fellowship at Boston Children’s Hospital and the Dana-Farber Cancer Institute.

Research Funding

  • Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency
    NIH · U01AI126612 · Aug 24, 2017 – Jul 31, 2024 · Role: Principal Investigator
  • University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG)
    NIH · P30CA014089 · Apr 1, 1980 – Nov 30, 2026 · Role: Principal Investigator
  • Pediatric Graft-vs-Host Disease
    NIH · Z01BC010596 · Role: Principal Investigator
  • Pediatric Oncology Branch Clinical Care and Education
    NIH · Z01BC010764 · Role: Principal Investigator
  • Experimental Therapeutics of Pediatric Hematopoietic Malignancies
    NIH · Z01SC010353 · Role: Principal Investigator
  • Pediatric Graft-vs-Host Disease
    NIH · ZICBC010596 · Role: Principal Investigator
  • Behavioral Science Core
    NIH · ZICBC011288 · Role: Principal Investigator
  • Experimental Therapeutics of Pediatric Hematopoietic Malignancies
    NIH · ZICSC010353 · Role: Principal Investigator
  • Pediatric Oncology Branch Clinical Care and Education
    NIH · ZIEBC010764 · Role: Principal Investigator

Publications

  • Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Cancers (Basel). 2024 Jan 24; 16(3).. View in PubMed
  • Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2023 03 01; 108(3):747-760.. View in PubMed
  • Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001). Haematologica. 2022 10 01; 107(10):2295-2303.. View in PubMed
  • Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects. Cancer Immunol Res. 2022 07 01; 10(7):856-870.. View in PubMed
  • Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Pediatr Blood Cancer. 2022 10; 69(10):e29812.. View in PubMed
  • Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Am J Hematol. 2022 05; 97(5):613-622.. View in PubMed
  • Managing therapy-associated neurotoxicity in children with ALL. Hematology Am Soc Hematol Educ Program. 2021 12 10; 2021(1):376-383.. View in PubMed
  • Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor. Mol Ther. 2022 03 02; 30(3):1215-1226.. View in PubMed
  • In vitro and in vivo effects of AVA4746, a novel competitive antagonist of the ligand binding of VLA-4, in B-cell acute lymphoblastic leukemia. Exp Ther Med. 2022 Jan; 23(1):47.. View in PubMed
  • Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021 06; 18(6):379-393.. View in PubMed